HLA G Antibody (01G) [Allophycocyanin/Cy7]

• Reactivity: Hu, Mu(-), Rt(-)
• Applications: Flow
• Clone: 01G
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Allophycocyanin/Cy7

HLA G Antibody (01G) [Allophycocyanin/Cy7] Summary

• Description: This conjugate is made on demand and is not held in inventory. Each order represents a unique lot. All conjugates are generated using validated conjugation protocols and meet strict degree of labeling (F/P) specifications; additional information is available upon request. The antibody concentration is provided on the individual product label.
  
  For specialized conjugation needs, like large quantities, specific concentrations, and defined F/P ratios, bulk and custom antibody conjugation services are available.
• Immunogen: HLA-B27 transgenic mice were imunized with H-2 identical murine cells transfected with and expressing genes encoding HLA G Antibody (01G) and human beta2-microglobulin.
• Specificity: The antibody 01G recognizes membrane-bound form of HLA-G (full-length HLA-G1), but not soluble forms. HLA-G belongs to the MHC Class I molecules (MHC Class Ib; nonclassical) and it is expressed on the surface of trophoblast cells.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: HLA-G
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry
• Application Notes: Optimal dilution of this antibody should be experimentally determined. For optimal results using our Tandem dyes, please avoid prolonged exposure to light or extreme temperature fluctuations. These can lead to irreversible degradation or decoupling. When staining intracellular targets, specific attention to the fixation and permeabilization steps in your flow protocol may be required. Please contact our technical support team at technical@novusbio.com if you have any questions. This conjugated antibody is not kept in inventory and is made to order using validated conjugation protocols.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark. Do not freeze.
• Buffer: PBS
• Preservative: 0.05% Sodium Azide
• Purity: Protein A purified

Notes

Cy is a registered trademark of Global Life Sciences Solutions Germany GmbH.

Alternate Names for HLA G Antibody (01G) [Allophycocyanin/Cy7]

• b2 microglobulin
• HLA class I histocompatibility antigen, alpha chain G
• HLA class I molecule
• HLA G antigen
• HLA G
• HLA-6.0
• HLA-G histocompatibility antigen, class I, G
• HLAG
• HLA-G
• major histocompatibility complex, class I, G
• MHC Class I Antigen G
• MHC class Ib antigen
• MHC-G
• mutant MHC class I antigen
• mutant MHC class Ib antigen
• sHLA-G
• Soluble HLA class I histocompatibility antigen, alpha chain G

Background

Human leukocyte antigen (HLA)-G is a non-classical major histocompatibility complex (MHC) class I gene belonging to the HLA class I family. The HLA class I family is subdivided into the classical (HLA-Ia) antigens comprised of HLA-A, -B, and -C molecules and the nonclassical (HLA-Ib) group including the HLA-E, -F, and -G molecules. Seven different splice variants of HLA-G have been observed including four membrane isoforms (HLA-G1, HLA-G2, HLA-G3, and HLA-G4) and three soluble isoforms (HLA-G5, HLA-G6 and HLA-G7). Proteolytic processing of HLA-G1 by metalloproteinases (MMPs) such as MMP-2 produces the soluble isoform, shedding HLA-G1. The HLA-G1 and HLA-G5 isoforms share a similar confirmation to the classical MHC class I protein, consisting of three extracellular domains including alpha1, alpha2, and alpha3 associated with Beta-2-microglobulin (B2M). Other HLA-G variants are shorter, missing one or two of the globular domains and are not bound to B2M. HLA-G receptors include KIR2DL4 (CD158d), with the highest affinity for ILT2 (LILRB1, CD85j) and ILT4 (LILRB2, CD85d) (1,2).

Discovered in cytotrophoblasts, HLA-G is involved in fetal maternal immune tolerance and some studies have linked its downregulation with severe preeclampsia (3). HLA-G mediated immune suppression works by impeding cell proliferation, differentiation, cytotoxicity, cytokine secretion and chemotaxis; and activation of regulatory cells and MDSCs or M2 type macrophage. HLA-G is constitutively expressed in immune-privileged sites such as pancreatic islets, mesenchymal stem cells (MSCs) and the cornea. Upregulation of HLA-G occurs in pathological states including cancer, allo-transplantations, viral infections, autoimmune and inflammatory diseases (4). In cancer, HLA-G expression is induced by hypoxia and has been correlated with advanced tumor stage, tumor metastasis, and poor therapeutic response and survival. HLA-G is an attractive tumor associated-antigen (TAA) for immunotherapy and is considered a major immune checkpoint (ICP).

References

1. Loustau, M., Anna, F., Drean, R., Lecomte, M., Langlade-Demoyen, P., & Caumartin, J. (2020). HLA-G Neo-Expression on Tumors. Front Immunol, 11:1685. PMID: 32922387

2. Lin A, Yan WH. (2018) Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges. Front Immunol. 9:2164. PMID: 30319626

3. Djurisic S, Hviid TV. (2014) HLA Class Ib Molecules and Immune Cells in Pregnancy and Preeclampsia. Front Immunol. 5:652. PMID: 25566263

4. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. (2001) Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci U S A. 98(21):12150-12155. PMID: 11572934

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: HLA-G